HER2 Positive Breast Neoplasms
Showing 1 - 25 of >10,000
Breast Cancer Female Trial (Pyrotinib and Trastuzumab)
Not yet recruiting
- Breast Cancer Female
- Pyrotinib and Trastuzumab
- (no location specified)
Sep 11, 2023
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2
Recruiting
- HER2-positive Breast Cancer
- Early-stage Breast Cancer
- pyrotinib combined with Capecitabine
- treatment of physician's choice
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Sep 6, 2023
Early On-treatment Transcriptional Profiling as Predictor of
Recruiting
- HER2-positive Breast Cancer
- +2 more
- Trastuzumab (neoadjuvant)
- +2 more
-
Hospitalet de Llobregat, Barcelona, SpainInstitut Català d'Oncologia l'Hospitalet
Jun 12, 2023
HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)
Not yet recruiting
- HER2 Low Breast Carcinoma
- SHR-A1811 for injection
- (no location specified)
Jun 12, 2023
HER2-positive Advanced Breast Cancer Trial (DP303c, Trastuzumab, Vinorelbine Tartrate)
Not yet recruiting
- HER2-positive Advanced Breast Cancer
- DP303c
- +3 more
- (no location specified)
Jun 4, 2023
HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)
Not yet recruiting
- HER2-positive Breast Cancer
- 68Ga/131I-SGMIB-5F7
-
Shanghai, ChinaHuashan Hospital
Aug 1, 2023
Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)
Not yet recruiting
- Breast Cancer
- HER2-positive Breast Cancer
-
São Paulo, BrazilCentro Paulista de Oncologia (Oncoclínicas)
Oct 3, 2023
HER2-positive Advanced Breast Cancer Patients Treated With ADC
Recruiting
- Breast Cancer
- HER2 expression of circulating tumor cells
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
Apr 18, 2023
Sentinel Lymph Node Biopsy in Initially Lymph Node-positive,
Completed
- Breast Cancer
- Sentinel Lymph Node
- Test cohort
-
Fuzhou, Fujian, ChinaChuan Wang
Nov 25, 2023
HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Miami (Discontinuation of Anti-HER-2 Maintenance
Recruiting
- HER2-positive Metastatic Breast Cancer
- Stage IV Breast Cancer
- Discontinuation of Anti-HER-2 Maintenance Treatment
-
Miami, FloridaUniversity of Miami
Jul 17, 2023
Breast Cancer, Brain Metastases, Radiotherapy Trial in Shanghai (Combination use of SRT with T-DXd)
Not yet recruiting
- Breast Cancer
- +2 more
- Combination use of SRT with T-DXd
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Oct 14, 2023
Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Shanghai (proton plus carbon ion radiotherapy)
Recruiting
- Triple Negative Breast Cancer
- HER2-positive Breast Cancer
- proton plus carbon ion radiotherapy
-
Shanghai, ChinaShanghai Proton and Heavy Ion center
Jan 11, 2023
HER2-positive Breast Cancer Trial (Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without
Not yet recruiting
- HER2-positive Breast Cancer
- Standard of Care Adjuvant Breast Radiation
- Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
- (no location specified)
Jan 20, 2023
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,
Not yet recruiting
- HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
- SHR-A1811
- Trastuzumab Emtansine
- (no location specified)
Nov 7, 2023
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,
Not yet recruiting
- Breast Cancer Invasive
- +3 more
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 17, 2023
Breast Cancer With Brain Metastases Trial in Wuhan (pyrotinib+capecitabine+bevacizumab)
Recruiting
- Breast Cancer With Brain Metastases
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 22, 2023
t Pathologic Complete Response Observed in HER2 Positive Breast
Completed
- HER2+ Breast Cancer
-
Rawalpindi, Punjab, PakistanRawalpindi Medical University
Jun 26, 2023
HER2 Positive Early Breast Cancer Trial in Shanghai (Docetaxel, carboplatin, Trastuzumab)
Recruiting
- HER2 Positive Early Breast Cancer
- Docetaxel
- +5 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center Shanghai, China, 200032
Jun 6, 2023
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;
Recruiting
- Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
- dalpiciclib; fluvestrant; compound gossypol acetate tablets
-
Hangzhou, Zhejiang, ChinazhejiangCH
Nov 9, 2023
Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Albumin paclitaxel+trastuzumab+pyrrolitinib,
Active, not recruiting
- Breast Cancer
- HER2-positive Breast Cancer
- Albumin paclitaxel+trastuzumab+pyrrolitinib
- Docetaxel+Carboplatin+trastuzumab+Parstuzumab
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Jun 23, 2023
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)
Not yet recruiting
- Advanced Solid Tumor
- +8 more
- BGB-43395
- +2 more
- (no location specified)
Nov 13, 2023
HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,
Not yet recruiting
- HER2-PositiveRecurrent or Metastatic Breast Cancer
- SHR-A1811 Injection
- +2 more
- (no location specified)
Sep 21, 2023